GenFleet Therapeutics (Shanghai) Inc
GenFleet Therapeutics (Shanghai) Inc is a biotechnology company engaged in pharmaceuticals and medical research, primarily operating in the healthcare sector.
Business. GenFleet Therapeutics (Shanghai) Inc (2595.HK) is a biotechnology and medical research company headquartered in Shanghai. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
GenFleet Therapeutics (Shanghai) Inc (2595.HK) is a biotechnology and medical research company headquartered in Shanghai. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. It is primarily listed on the Hong Kong Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
GenFleet Therapeutics (Shanghai) Inc has a basic and diluted share count of 370,366,630, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's valuation snapshot is currently unavailable, limiting the ability to assess its relative value against industry benchmarks.
Profitability and return metrics are not available for GenFleet Therapeutics (Shanghai) Inc, which prevents a direct comparison with the preferred metrics of the Biotechnology & Medical Research industry. Without these metrics, it is not possible to determine whether the company is outperforming or underperforming its peers in terms of return on invested capital or operating margins.
The company's segment and geographic exposure are not disclosed in the available data, making it difficult to assess revenue concentration or geographic diversification. This lack of transparency could pose a risk to investors seeking to understand the company's exposure to regional economic or regulatory changes.
Looking ahead, the company's growth trajectory is unclear due to the absence of revenue history and outlook data. Analysts have provided a mean price target of 56.18 CNY, with a median of 55.63 CNY, suggesting a generally positive sentiment, but the lack of financial data limits the ability to validate these expectations.
Risk factors include the inability to assess liquidity risk, which could affect the company's ability to meet short-term obligations. The dilution risk is currently low, but the absence of detailed financial disclosures means that potential dilution sources cannot be identified.
Recent events, including filings and transcripts, are not available in the provided data, which limits the ability to assess the company's recent strategic or operational developments.
- GenFleet Therapeutics (Shanghai) Inc has no immediate dilution pressure based on current share counts.
- Analysts have assigned a generally positive outlook, with a mean price target of 56.18 CNY.
- The company's liquidity risk could not be assessed due to missing balance-sheet data.
- Profitability and return metrics are not available, limiting the ability to compare with industry benchmarks.
- The company's geographic and segment exposure is not disclosed, reducing transparency for investors.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥130.3M, +24,4% YoY; Operating income +2,9% YoY.
- ▍Revenue ¥130.3M, +24,4% YoY
- ▍Operating income +2,9% YoY
- ▍Net income −164,8% YoY
- ▍Net margin -1377.6%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,59 |
| Revenue | —no estimate | —no estimate | 185,2M CNY |
| Operating income | —no estimate | —no estimate | -236,1M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- GenFleet Therapeutics (Shanghai) Inc Market data — financials · 2026-05-26
- GenFleet Therapeutics (Shanghai) Inc Market data — analyst estimates · 2026-05-26